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ABSTRACT 
AIMS: Accurate histologic diagnosis and classification of germ cell tumors (GCTs) is key to 
informing successful therapeutic and surveillance strategy.  Modern therapeutic approach for 
yolk sac tumor (YST) is highly curative.  Because YST takes on a large morphologic 
spectrum, it can be confused for other GCT subtypes as well as somatic carcinomas, 
particularly when YST presents in an extragonadal or a metastatic setting.  Currently 
available immunohistochemical markers are limited by suboptimal sensitivity and specificity. 
We recently reported that ZBTB16 is a sensitive and specific marker for testicular YST.  
ZBTB16 is absent in other GCTs and in most common somatic carcinomas, including these 
of gastrointestinal, pancreatobillary, respiratory, genitourinary and gynecologic tracts.  The 
purpose of this study is to investigate the diagnostic utility of ZBTB16 in the settings of 
metastatic and extragonadal YST.  
METHODS AND RESULTS: We studied 32 archived metastatic and 4 extragonadal primary 
YSTs as well as 51 somatic malignancies for their immunohistochemical expression of 
ZBTB16. For comparison, AFP and Glypican-3 were also studied in parallel. Our results 
demonstrated an overall sensitivity of 91.6% for ZBTB16 in detecting metastatic and 
extragonadal YSTs. The non-YST elements (teratoma and embryonal carcinoma) in 15 YST-
containing metastatic mixed GCTs were nonreactive. With exception of occasional 
myoepithelial cells of salivary gland carcinoma, all the 51 somatic malignancies were 
negative for ZBTB16.   
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CONCLUSION: ZBTB16 is a sensitive and specific marker for YST and is diagnostically 
superior to AFP and Glypican-3 in metastatic and extragonadal settings.   
Key words: ZBTB16, yolk sac tumor, metastatic, extragonadal 
 
INTRODUCTION 
Accurate histologic diagnosis and classification of germ cell tumors (GCTs) is key to 
informing successful treatment and surveillance strategy.  Modern therapeutic approach for 
yolk sac tumor (YST) is highly curative with a survival rate of greater than 90% (1).  Because 
it takes on a large morphologic spectrum, YST has been the most commonly underdiagnosed 
element among the testicular GCTs (2-4). It can be confused for other GCT subtypes as well 
as primary somatic neoplasms, particularly when YST presents as an extragonadal primary or 
as a metastasis to other organs. This could lead to improper selection of therapeutic as well as 
biochemical surveillance strategy. Several ancillary markers have been used to facilitate the 
diagnosis of GCT, including the early marker, like placental-like alkaline phosphatase 
(PLAP), and the more recent ones – OCT4, SOX2 and SALL4. Although these markers are 
sensitive for GCTs, they lack specificity for subtyping GCTs (5, 6). There are currently 
limited YST immunohistochemical markers. α-fetoprotein (AFP) is a marker moderately 
specific for YST, but with a relatively low sensitivity, particularly for YST with glandular 
pattern (2-4).  In addition, protein expression of AFP in YST may be lost in metastatic or 
post-treatment settings (7, 8).  Furthermore, AFP is also expressed in some primary somatic 
neoplasms, such as hepatocellular carcinoma, hepatoid adenocarcinoma of the stomach, and 
clear cell carcinomas of mullerian origin (9-11).  Another recently identified YST marker is 
GPC-3 (12, 13); however, its expression has been reported in other GCT subtypes, such as 
choriocarcinoma and, less frequently, teratoma and embryonal carcinoma (12, 13), as well as 
some primary somatic neoplasms (12, 14-17).  Because of these limitations, a diagnostic 
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immunohistochemical panel, including markers of pluripotentiality (SALL4 and LIN28) and 
endodermal identity (AFP, GPC-3 and villin), is recommended to overcome the diagnostic 
challenges of multiple patterns of differentiation in YSTs (18).      
Zinc finger and BTB (Broad/complex/Tramtrack/Bric a Brac) domain containing 16 
(ZBTB16) was first identified in a patient with acute promyelocytic leukemia. It is a zinc 
finger transcription factor belonging to the POZ (POxvirus and Zinc finger) -Krüppel family 
that binds to specific DNA sequences with its carboxy-terminal zinc fingers and suppresses 
transcription by recruiting co-repressors with its aminoterminal POZ domain (19, 20). 
ZBTB16 affects diverse signaling pathways, including cell cycle, differentiation, and 
programmed cell death pathways in hematopoietic cells as well as solid tumors (20-23). It is 
involved in major developmental and biological processes, such as spermatogenesis and stem 
cell maintenance, hind limb formation, hematopoiesis, immune regulation, and oncogenesis 
(19-21). In normal testes, ZBTB16 is expressed specifically in undifferentiated 
spermatogonial cells (19, 24). Studies have implied that ZBTB16 serves to promote 
spermatogonial stem cell self-renewal (19, 24) and plays a key role in the maintenance of 
normal spermatogenesis. Infertility is observed in ZBTB16-null mice due to the impairment 
of spermatogonial stem cell self-renewal and subsequent exhaustion of spermatogonia (24, 
25). Although the function of ZBTB16 in spermatogenesis is relatively well studied, 
expression of ZBTB16 in GCTs has just been explored. We recently reported that, in testis, 
ZBTB16 is specifically expressed in YST, carcinoid and spermatocytic tumor but not in other 
GCT subtypes. Somatically, ZBTB16 is mainly expressed in prostate adenocarcinoma (23) 
and some carcinoid tumors (26). It is absent in most of the other common somatic tumors, 
including those of gastrointestinal, pancreatobillary, respiratory, genitourinary and 
gynecologic tracts (27). 
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The aim of this study was to investigate the diagnostic utility of immunohistochemical 
expression of ZBTB16 in the detection of metastatic and extragonadal YSTs. The diagnostic 
value of ZBTB16 will also be compared against AFP and GCP-3.   
 
MATERIAL AND METHODS 
Tissue samples 
This study was approved by the relevant institutional review boards. A total of 32 
metastatic YST-containing GCTs and 4 extragonadal primary YSTs accessioned between 
2010 - 2016 were retrieved from the archives of two academic institutions. Among the 32 
metastatic GCTs, 17 were pure YSTs, and 15 were mixed GCTs containing 5%-95% of YST 
element. The non-YST components in the metastatic mixed GCTs included teratoma (13 
cases) and embryonal carcinoma (6 cases). Of the metastatic YSTs, 24 were obtained prior to 
chemotherapy, 8 were recurrent YSTs after chemotherapy.  Most of the YSTs exhibited 
multiple morphologies (e.g. cystic, glandular, papillary, and solid). The sites of the 
metastases included retroperitoneum (22 cases), mediastinum/neck (5 cases), lower abdomen 
and pelvis (5 cases), and lung (1 case).  The primary non-testicular extragonadal YSTs 
included 1 mediastinal, 1 retroperitoneal, 1 liver and 1 urinary bladder primaries. All the 
extragonadal YSTs were pure YSTs. The diagnosis of YST was established by clinical 
history including serum markers, histomorphology and/ or the results of 
immunohistochemical markers - AFP, GPC-3, SALL4, OCT4, PLAP, CD117, D2-40, and /or 
CD30.  
Besides the somatic tumors that we have previously studied (23, 27, 28), fifty-one 
primary somatic malignancies, many of which exhibit morphologic overlap with YST, were 
evaluated for the immunohistochemical expression of ZBTB16. They included 8 breast 
carcinomas (4 ductal and 4 lobular carcinomas), 8 melanomas, 5 lymphomas (1 diffuse large 
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cell lymphoma, 1 Hodgkin’s lymphoma, 1 T cell lymphoma, 2 CD30-positive malignant 
lymphomas), 3 pancreatobiliary carcinomas, 6 combined small cell carcinomas and urothelial 
carcinomas of urinary bladder, 7 head neck carcinomas (1 poorly differentiated non-
keratinizing squamous cell carcinoma , 6 salivary gland carcinomas), 3 mesotheliomas, 2 
synovial sarcomas, 2 renal cell carcinomas, 2 poorly differentiated carcinomas of mullerian 
origin, 2 colorectal carcinomas, 2 merkel cell carcinomas, and 1 adrenocortical carcinoma. 
 
Immunohistochemistry 
For ZBTB16 immunohistochemistry, following deparaffinization and rehydration, 
charged slides with 5-μm thick sections of tissue were treated with 3% hydrogen peroxide 
(H2O2) to eliminate endogenous peroxidase activity, then processed for antigen retrieval with 
10-mM citrate buffer pH 6.0 using a pressure cooker (Pascal; Dako Cytomation, Glostrup, 
Denmark) for 1 minute at 125°C, followed by slow cooling. The rest of the procedure was 
done in a DAKO automated instrument. All sections were rinsed with phosphate-buffered 
saline (137 mM NaCl, 2.7 mM potassium chloride, 4.2 mM sodium phosphate, and 1.5 mM 
potassium phosphate) and reacted with mouse anti-ZBTB16 antibody (D-9; sc-28319, Santa 
Cruz Biotechnology, Santa Cruz, CA) for 1.5 hours at 1:500 dilution in phosphate-buffered 
saline containing 1% bovine serum albumin (BSA) and 5% normal goat serum at room 
temperature. The sections were then incubated for 20 minutes with EnVision+ System 
horseradish peroxidase-labeled polymer conjugated with biotinylated anti-mouse secondary 
antibody and 3,3'-diaminobenzidine substrate. Laboratory validated AFP and GPC3 
immunohistochemistry was performed in an automated DAKO platform in the same way as 
clinical samples. All slides were counterstained with hematoxylin, dehydrated, and cover 
slipped. 
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Analysis of immunohistochemical staining  
Tumor cells were analyzed for ZBTB16 immunoreactivity in a semiquantitative way. 
Each histologic component of the mixed GCT, when present, was independently evaluated. 
Histologic patterns/subtypes of YST were assessed individually for their immunoreactivity 
with ZBTB16, AFP and GPC-3, respectively. Only nuclear staining for ZBTB16 and 
cytoplasmic staining for AFP and GPC-3 were considered positive. Based on the extent of the 
immunoreactivity, the staining was graded as: virtually no (<1% cells) staining (negative), 1-
25% of cells staining (focal), 25%-50% of cells staining (moderate extent) and >50% of cell 
staining (extensive/diffuse). For ZBTB16, normal testicular tissue sections containing 
ZBTB16-positive spermatogonial cells and ZBTB16-negative stromal cells were used as 
positive and negative testing controls, respectively.  
 
RESULTS 
I. Expression of ZBTB16 in metastatic YST  
Twenty-nine of the 32 metastatic YSTs showed immunoreaction with ZBTB16: 13/32 
(41%) had diffuse, 9/32 (28%) had moderate, and 7/32 (22%) had focal nuclear expression. 
Three (9%) cases had no immunoreactivity with ZBTB16 (1 reticular, 1 solid, and 1 
polyvesicular). ZBTB16 reactivity/grade appeared not associated with specific histologic 
growth patterns. In 15 cases of the mixed GCTs, all non-YST GCT components (teratoma 
and/or embryonal carcinoma) were nonreactive with ZBTB16 (0/15, 0%). The overall 
sensitivity of ZBTB16 in detecting metastatic YST was 29/32 (91%). Seven of 8 (88%) 
postchemotherapy metastatic YSTs were immunoreactive for ZBTB16 with 50% (4/8) of the 
cases exhibiting diffuse cell staining, 25% (2/8) with moderate extent of cell staining, and 
13% (1/8) with focal cell staining. Only one (13%) postchemotherapy metastatic YST did not 
stain. Twenty-two of 24 (92%) metastatic YSTs without prior treatment were positive for 
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ZBTB16 with 38% (9/24) of the cases showing diffuse, 29% (7/24) moderate, and 15% 
(6/24) focal staining. Only two cases (8%) were nonreactive. ZBTB16 showed no statistically 
significant difference in sensitivity for detecting metastatic YSTs between the non-treated 
and the chemotherapy treated YSTs (p<0.005). The results of ZBTB16 expression in 
extragonadal primary and metastatic YSTs are summarized in Table 1. Immunohistochemical 
expression of ZBTB16 in a representative case of metastatic YSTs is illustrated in figure 1. 
The overall sensitivity of ZBTB16 in detecting primary extragonadal YST was 100% (4/4). 
The overall sensitivity of ZBTB16 in detecting both metastatic YST and extragonadal YST 
was 91.6% (33/36).  
 
II. Expression of ZBTB16 in extragonadal YST:  
  The 4 extragonadal primary YSTs presented either as solid pattern, partially glandular 
or a mixture of both, mimicking moderately to poorly differentiated somatic malignancies. 
All the 4 extragonadal primary YSTs were strongly and diffusely reactive with ZBTB16 (4/4, 
100%). Figure 2 illustrates a liver primary YST (hematoxylin-eosin) and 
immunohistochemical expression of ZBTB16 in tumor cells. The results of ZBTB16 
immunohistochemical expression in the metastatic YST-containing GCTs and primary 
extragonadal YSTs are summarized in table 1.  
 
III. Comparison of the immunoreactivity of ZBTB16 with AFP and GPC3  
Of the thirty-two cases of metastatic YSTs in our case series, twenty-nine were 
available for immunohistochemical study with AFP and GPC3. The results are summarized 
in table 2. The detecting sensitivity of ZBTB16, AFP and GPC-3 for those 29 cases was 
89.7%, 58.6% and 86.2%, respectively. Although there was no association in the 
immunoreactivity of AFP and GPC-3 with specific YST histologic patterns, AFP displayed a 
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trend for nonreactivity in solid. Both AFP and GPC3 were nonreactive in the sarcomatoid 
YST case, with which, interestingly, ZBTB16 showed focal reactivity. Nevertheless, those 
pattern-related immunoreactivity differences warrant further validation with a larger number 
of cases.  
 
IV. Expression of ZBTB16 in somatic malignancies  
We have previously demonstrated that ZBTB16 nuclear expression was absent in 
most of the somatic carcinomas, except reactivity in prostate cancers and weak and focal 
positivity in approximately one third of hepatocellular carcinomas (23, 28). With the 
exception of occasional ZBTB16 positive myoepthelial cells in the salivary gland carcinomas 
(adenoid cystic and acinar cell carcinoma), all the 51 somatic malignancies in this study were 
negative for ZBTB16. These results indicate that ZBTB16 is highly specific for YST. The 
results of ZBTB16 expression in the somatic malignancies are summarized in table 3.  
 
DISCUSSION 
It is estimated that 3% to 5% of newly diagnosed cancers present without established 
primary sites (29).  YST notoriously displays diverse histologic patterns, which can mimic 
many different types of tumors – GCTs and somatic malignancies alike.  Proliferative or 
hyperplastic endodermal glandular epithelium of teratoma and somatic adenocarcinoma can 
be mistaken for glandular YST (2-4, 30). Seminoma and poorly differentiated somatic 
malignancies can be simulated by solid YST (31), particularly in small biopsies or suboptimal 
specimens. In later recurrence of GCTs, YST commonly presents as a glandular and/or solid 
tumor, which, without prior clinical information, may lead to erroneous diagnosis of a 
somatic-type malignancy.  All those make YST one of the most challenging malignancies to 
diagnose, particularly in the setting of extragonadal location and unknown clinical history.  
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Distinction of YST from other GCTs (especially metastatic teratoma and seminoma) as well 
as from somatic malignancies is of critical importance because of different implications for 
treatment as well as prognosis and tumor biomarker surveillance.  For example, metastatic 
teratoma is usually treated by surgery alone, while the presence of YST requires additional 
adjuvant chemotherapy (32-34).  Furthermore, presence of YST in metastases increases the 
chances of recurrence despite additional therapy and portends an overall worse prognosis.  
Sensitive and specific markers for YST are therefore extremely valuable in helping reach 
correct diagnosis and informing optimal management  strategy. 
AFP is a useful traditional marker for YST, nevertheless, it is limited by low 
sensitivity with an immunoreactive positive rate as low as 60% (11).  In addition, its staining 
is frequently focal and patchy (9, 35), contributing to false negative immunoreactivity in 
small biopsy specimens (9, 35). AFP has also been reported to stain embryonal carcinoma 
and teratoma (36, 37) as well as somatic tumors, such as ovarian serous adenocarcinoma (38), 
clear cell adenocarcinoma (9), pancreatic adenocarcinomas (7), hepatocellular carcinoma (8), 
and gastric carcinoma (39) 
GPC-3 is another GCT marker that was recently identified to be valuable for 
diagnosis of YST.  It has been reported that GPC-3 is more sensitive than AFP (12, 14), but 
might not be as specific as AFP for YST.  Expression of GPC-3 has been reported in 
embryonal carcinoma, choriocarcinoma, and teratoma as well as somatic tumors, including 
hepatocellular, gastric, and lung carcinomas (12, 14-17). 
In our previous study, we have showed that ZBTB16 is highly sensitive and specific 
for testicular YST (40). In this current study, we further demonstrated that ZBTB16 was also 
a sensitive marker for extragonadal and metastatic YSTs with an overall sensitivity of 91.6%, 
superior to AFP and GPC-3.  
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Although ZBTB16 is expressed in some somatic tumors, including low grade and a 
portion of high grade prostatic carcinoma (23), some carcinoid tumor (26) as well as about 
30% of hepatocellular carcinomas (with focal and weak positivity) (28), ZBTB16 nuclear 
expression is rarely seen in other somatic malignancies, particularly the common insidious 
and specific-marker-lacking malignancies, such as pancreatobilliary and upper 
gastrointestinal carcinomas. Due to the availability of tissue specific markers for prostatic 
carcinoma, hepatocellular carcinoma and carcinoid tumor, distinction of YST from these 
ZBTB16-expressing somatic tumors should be less problematic.  ZBTB16 is, therefore, an 
excellent adjunct marker with high sensitivity and specificity in distinguishing extra-testicular 
primary YST as well as metastatic YST from its mimics.  The other advantage of ZBTB16 is 
its nuclear staining which makes it easy to interpret. Unlike the cytoplasmic staining of AFP 
and GPC-3, nuclear ZBTB16 immunostaining is less affected by hemorrhage, serum and 
secretions, or necrosis, thus the background staining is minimal.  Moreover, when necessary, 
ZBTB16 in paneling with other GCT markers (e.g. SALL4, AFP or GPC-3) should further 
increase the sensitivity and confidence in the diagnosis of YST for challenging cases. 
In summary, the results of this study demonstrate that ZBTB16 is a novel sensitive 
and specific nuclear marker in the detection of metastatic and extragonadal YSTs.  
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TABLES 
Table 1: Immunohistochemical expression of ZBTB16 in primary extragonadal YSTs and 
metastatic YST-containing GCTs 
Table 2. Immunohistochemical expression of ZBTB16 in somatic malignancies 
Table 3. Growth patterns and immunoreactivity of metastatic YSTs with ZBTB16, AFP and 
GPC-3. 
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FIGURE LEGENDS 
 
Figure 1: Expression of ZBTB16 in metastatic YST: A (Hematoxylin and Eosin) and B 
(immunohistochemistry) - Moderate extent of ZBTB16 positivity in metastatic 
retroperitoneal YST with reticular pattern. C (Hematoxylin and Eosin) and D 
(immunohistochemistry) - Diffuse ZBTB16 immunoreactivity in metastatic mediastinal YST 
with mostly solid growth pattern. E (Hematoxylin and Eosin) and F (immunohistochemistry) 
- Metastatic omental mixed germ cell tumor showing focal YST element being highlighted by 
ZBTB16 immunostaining.  
 
Figure 2: Expression of ZBTB16 in primary liver YST from a 76 year-old male. A and B 
(Hematoxylin and Eosin, low and high magnification) - Poorly differentiated carcinoma with 
vague glandular formation. C (Immunohistochemistry) - Diffuse and strong immunoreactivity 
of tumor cells with ZBTB16.  
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Table 1: Immunohistochemical expression of ZBTB16 in primary extragonadal YSTs and metastatic YST-containing GCTs 
 
GCT = germ cell tumor; YST = yolk sac tumors; EC = embryonal carcinoma; T = teratoma; LN = lymph node 
Diagnosis and %YST in GCT number of 
cases 
Composition  
of GCT 
Location ZBTB16 Positivity 
of YST element 
ZBTB16 positivity  
of non-YST element 
Primary extragonadal YST  
100% YST (pure YST) 4 YST (4/4) 
 
Retroperitoneum (1/4) 
Mediastinum (1/4) 
Liver (1/4) 
Bladder (1/4) 
3+ (4/4; 100%) NA 
Metastatic mixed GCT, no chemotherapy  
YST< 50%  
 
 
 
YST50% 
 
 
6 
 
 
 
18 
 
 
 
T+ EC+ YST (3/6) 
T+YST (3/6) 
 
 
YST (14/18) 
T+YST (3/18) 
EC+YST (1/18)  
Retroperitoneal LN (6/6) 
 
 
 
Retroperitoneal LN (10/18) 
Mediastinal LN (4/18) 
Abdomen (2/18) 
Lung (1/18) 
Pelvic LN (1/18) 
3+ (1/6; 17%) 
2+ (3/6; 50%) 
1+ (2/6; 33%) 
 
3+ (8/18; 44%) 
2+ (4/18; 22%) 
1+ (4/18; 22%) 
0   (2/18; 11%) 
0 (0/6, 0%) 
 
 
 
0 (0/4, 0%) 
Metastatic mixed GCT, postchemotherapy  
YST< 50% 
 
 
YST50% 
2 
 
 
6 
T+YST (2/2) 
 
 
YST (3/6) 
T+YST (1/6) 
T+EC+YST (1/6) 
EC+YST (1/6) 
Retroperitoneal LN (1/2) 
Renal vein (1/2) 
 
Retroperitoneal LN (4/6) 
Mediastinal LN (1/6) 
Pelvic LN (1/6) 
3+ (1/2; 50%) 
1+ (1/2; 50%) 
 
3+ (3/6; 50%) 
2+ (2/6; 33%) 
0   (1/6; 17%) 
0 (0/2, 0%) 
 
 
0 (0/3, 0%) 
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Table 2: Growth patterns and immunoreactivity of metastatic YSTs with ZBTB16, AFP and GPC-3 
Case  No Tumor growth patterns ZBTB16 AFP GPC-3 
1 Myxomatous  2+ 3+ 2+ 
2 Reticular+macrocystic 2+ Neg 2+ 
3 Sarcomatoid 1+ Neg Neg 
4 Reticular 3+ 3+ 3+ 
5 Polyvesicular + glandular 3+ 2+ 2+ 
6 Endodermal sinus+reticular 3+ 3+ 2+ 
7 Reticular +glandular 2+ 3+ 2+ 
8 Reticular 3+ 3+ 2+ 
9 Reticular 1+ Neg 1+ 
10 Endodermal sinus +papillary 3+ 3+ 3+ 
11 Myxomatous 1+ 1+ 1+ 
12 Reticular 3+ Neg 1+ 
13 Reticular 3+ 3+ 3+ 
14 Solid+ endodermal sinus 2+ 2+ 2+ 
15 Polyvesicular+ macrocystic 2+ 2+ 2+ 
16 Reticular Neg Neg 1+ 
17 Reticular 1+ Neg Neg 
18 Papillary 3+ Neg 2+ 
19 Reticular+glandular 1+ Neg 2+ 
20 Reticular 3+ Neg 3+ 
21 Glandular 2+ 1+ 1+ 
22 Solid Neg Neg 1+ 
23 Polyvesicular+ reticular 3+ 3+ 1+ 
24 Polyvesicular Neg 1+ Neg 
25 Solid 2+ Neg 3+ 
26 Glandular+ reticular 2+ Neg 1+ 
27 Endodermal sinus 1+ 2+ Neg 
28 Myxomatous 1+ 1+ 1+ 
29 Endodermal sinus 3+ 2+ 2+ 
Neg. negative 
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Table 3: Immunohistochemical expression of ZBTB16 in additional somatic malignancies 
   
Diagnosis # of cases  ZBTB16 immunoreactivity 
Breast carcinoma 8 Negative 
Melanoma 8 Negative 
Lymphoma 5 Negative 
Pancreatobilliary carcinoma 3 Negative 
Combined small cell 
carcinoma and urothelial 
carcinoma 
6 Negative 
Salivary gland  carcinoma 7 Negative, occasional 
myoepithelial cell positive 
Mesothelioma 3 Negative 
Adrenocortical carcinoma 1 Negative 
Synovial sarcoma 2 Negative 
Renal cell carcinoma 2 Negative 
Mullerian carcinoma 2 Negative 
Colorectal carcinoma 2 Negative 
Meckel cell carcinoma 2 Negative 
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